batoclimab
Batoclimab is a subcutaneous monoclonal antibody developed by Immunovant that blocks the neonatal Fc receptor (FcRn) — a protein in blood vessel walls that recycles immunoglobulin G (IgG) antibodies back into circulation. In autoimmune diseases driven by pathogenic IgG antibodies, blocking FcRn prevents this recycling, accelerating the breakdown of harmful antibodies and reducing disease activity. Batoclimab is in Phase 3 trials for generalized myasthenia gravis; a known class effect of FcRn inhibitors — including the approved competitor VYVGART (efgartigimod) — is LDL cholesterol elevation, which is monitored as a safety endpoint across all batoclimab trials.
Upcoming catalysts
Programs
Myasthenia Gravis
Generalized myasthenia gravis is a chronic autoimmune disease in which pathogenic IgG antibodies target acetylcholine receptors at the neuromuscular junction, causing fluctuating muscle weakness, ptosis, and potentially life-threatening respiratory failure. The FcRn inhibitor efgartigimod (VYVGART, argenx) is approved in gMG; this Phase 3 trial tests batoclimab's ability to reduce IgG burden and improve MG-ADL scores versus placebo while characterizing LDL cholesterol elevation — a known class effect of FcRn inhibition. Topline data are expected September 2026.